Skip to main content

Table 2 Clinical comparison of multiple primary lung adenocarcinomas in different EGFR and ALK status (in pre-patients)

From: CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas

Variable EGFR+ (n = 43) EGFR- (n = 24) Total P ALK+ (n = 13) ALK-(n = 54) Total P
Age 56 ± 6 60 ± 8 58 ± 7 0.068 49 ± 7 58 ± 7 58 ± 7 0.002*
Gender     0.011*     0.099
 Male 10(23) 13(54) 23(34)   7(54) 16(30) 23(34)  
 Female 33(77) 11(46) 44(66)   6(46) 35(4) 44(66)  
History of smoking 8(19) 10(42) 18(27) 0.041* 2(14) 16(30) 18(27) 0.010*
Lymph node metastasis 10(23) 16(67) 26(30) <0.001* 5(38) 8(15) 26(39) 0.110
  1. * P values were based on comparisons between the two groups
  2. EGFR epidermal growth factor receptor, ALK anaplastic large-cell lymphoma kinase
  3. EGFR +, EGFR mutation; EGFR-, EGFR wild type mutation; ALK +, ALK positive; ALK-, ALK negative